User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.00 -1.56% 886.00 870.00 890.00 895.00 875.00 895.00 74,149 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 659

Maxcyte Share Discussion Threads

Showing 651 to 675 of 725 messages
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
20/4/2021
12:53
AdamB - presumably they are using MXCT equipment/products/licenses? Not mentioned in article, so wanted to be sure.
cooltools
20/4/2021
12:46
Ka-ching! (well, at some point in the future...) hxxp://www.globenewswire.com/news-release/2021/04/20/2213128/0/en/Vertex-Pharmaceuticals-and-CRISPR-Therapeutics-Amend-Collaboration-for-Development-Manufacturing-and-Commercialization-of-CTX001-in-Sickle-Cell-Disease-and-Beta-Thalassemia.html
adamb1978
20/4/2021
10:53
On the R&D side maxcyte have a new product launch this year - perhaps a lot of the heavy lifting has been done already over the last 15years? Cash is needed for commercial scale up / roll out for partners as they need to scale as opposed to R&D as I understand it. And on the sales staff front, maxcyte is currently the only commercial option (hence the sales / royalty model)... and everyone in the cell engineering industry has already heard of them and know maxcyte have the FDA master file... so no point spending on sales teams if they are not required. I would have thought spending on legal more important. However seems like a perfectly reasonable question to ask them in a presentation down the line. Im certainly pleased they aren't spending money unnecessarily.
nimbo1
20/4/2021
10:20
"This stage in the companies life?" It's a young company - one would expect increases the biggest increases in staff costs in R&D and Sales, both driving Revenue.
trident5
20/4/2021
09:29
This stage in the companies life? They are only just about to enter their true growth stage which will last for the next 5-10 years...gearing up for that seems sensible to me. Or are you saying you expected more to be spent on research? Anyhow if one is dissatisfied they always have the option of taking capital else where. What I am disappointed in is no nasdaq mention, no mention of what the growth rate increase previously mentioned looks like and no invite for PI's to the analyst call at 2pm... But these were backwards looking results so there is plenty of time to enjoy thoughts of the future in the next updates.
nimbo1
20/4/2021
09:11
Disappointing that at this stage in the company's life that spends on R&D and Sales and Marketing are only up slightly on last year, but Admin costs are up by nearly 40%! And not much stock compensation headed to the sales team. Again, mostly directed at Admin.
trident5
20/4/2021
08:54
They told us the results in the last trading update - don't know how they could have been anything different. Agreed Adam - although its annoying the analyst call @2 isn't available for everyone.
nimbo1
20/4/2021
08:52
As expected. Ron Barron bought in at £7. DYOR and you'll see he will want to own for the long term and get a big bagger.
donald pond
20/4/2021
08:24
Underwhelming?
trident5
20/4/2021
07:49
Results look fine, and as expected. Continued growth, continued progress - this is a long term hold for me so I dont need to see rocket fuel in every set of figures! The one element was missing was the mention of the Nasdaq dual-listing! My guess is therefore that its imminent, potentially even today and announced before US markets open? I struggle to see why there wouldnt be a mention of it. They wont have killed it given the new investors are expecting it and you'd still expect them to mention it if they had done so
adamb1978
16/4/2021
10:41
hTTps://open.spotify.com/episode/4SebNzNjbEXJuJUPECuWT9?si=3HEo4XC-Ty2u6cqj6ASO-A&utm_source=copy-link&nd=1 Thanks to Sahara for sending me this - very interesting (short podcast). What it underlines is maxcyte's importance in the gene editing space when it comes to the practical side of mass delivery (assuming we get there)...because the manufacturing of the allogeneic treatments is as important as the science of crispr itself in terms of the commercial reality of it all.
nimbo1
15/4/2021
23:29
Couple of chunky late reported trades worth £357k means things may be stirring...
cooltools
15/4/2021
16:14
Interesting to see that all the old corporate material (ending 2016) on the Nasdaq site has been removed in the past few hours. We could hope it may be in preparation for a new listing!?! EDIT - old documents have re-appeared. hTTps://www.nasdaq.com/market-activity/stocks/maxc/sec-filings
pob69
15/4/2021
14:22
not surprising it is taking Time to digest the large move up imo...always happens
nimbo1
15/4/2021
13:44
There mustbe a bit of an overhang looking at today's trades, hopefully swallowed whole next week.
assagai
15/4/2021
07:33
Yes, I would be surprised if we don't get an update on NAS listing. With results seems an obvious opportunity. Fingers xxxd
assagai
15/4/2021
07:19
Results on the 20th April - we know what they are give or take due to detailed trading update. Interesting for me will be what 'acceleration of growth' actually means if any hints given for the coming year. I assume we'll also get a timetable for US listing plans.
nimbo1
14/4/2021
13:16
Reference to Maxcyte in this article "...Kohli says that a lot of the opportunities for licencing the CRISPR-Cas9 technologies are already priced into companies like CRISPR Therapeutics and MaxCyte. “There is probably still a lot of long-term upside to be gained by investing in the platforms, and I suspect that these types of companies will stay high return on invested capital companies rather than fading out as that time progresses. But just as exciting is the opportunity to invest in some of the companies that are looking to use the ‘genetic scissors’ to create new products.”" hTTps://www.cityam.com/london-investor-tej-kohli-on-chasing-the-second-wave-of-crispr-cas9/
pob69
14/4/2021
09:33
Could well be but last year 21st, a Tuesday. 2019 24th , a Wednesday.
assagai
14/4/2021
09:20
Assagai, Based on last year I thought Tuesday 20/4/2021. CNBC saying, Elsewhere, Wood said the genomics space is also set to hit escape velocity. “DNA sequencing is going to introduce science into healthcare decision making for the first time,” said Wood. “We can honestly say that until now more than half of all healthcare decisions were in some part made through guesses or experiences. Now we’re going to have the data.” ARK’s Genomics ETF has big bets on Exact Sciences, which makes up nearly 5% of the ETF, and Invitae. CRISPR Therapeutics is another major holding in the ETF. “We’re going to be able to cure diseases that we never thought it would be possible to cure, including cancer,” said Wood.
bamboo2
14/4/2021
09:18
Results within 2 weeks? Optimistic..
assagai
14/4/2021
09:06
Added a few more. Spread just 1p at present, 844-845 Odd, just noticed I can buy at 844 and sell at 845!
bamboo2
14/4/2021
08:47
Last trade of 591 was a buy
montynj
07/4/2021
15:05
Bought back a few yesterday and today at 869 and 869.9
bamboo2
23/3/2021
18:56
Nice find by Sahara 'Interesting study by Glaxo comparing Maxcyte $MXCT to the distant #2 in electroporation Lonza First time I've seen the difference quantified in a head-to-head comparison.' hTTps://twitter.com/saharainvesting/status/1374432147394629644?s=19
homebrewruss
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 13:16:20